Britain pushes G7 for faster vaccine development, sets 100-day target

Published 02/18/2021, 05:39 PM
Updated 02/18/2021, 05:40 PM
© Reuters. COVID-19 vaccinations in London

LONDON (Reuters) - Britain will challenge fellow G7 countries to help speed up the development of future vaccines to 100-days on Friday when Prime Minister Boris Johnson hosts a virtual meeting of leaders including U.S. President Joe Biden.

Johnson's Britain holds the presidency of the Group of 7 developed economies in 2021 and wants to use it to build momentum for a more coordinated approach to future pandemics, including the creation of a global health treaty.

The 1400 GMT call will be Biden's first multilateral engagement since he took over from Donald Trump whose unorthodox approach to G7 meetings often left attempts to build international consensus in disarray.

Johnson wants to seize on the change in U.S. leadership and the trail of destruction left by the COVID-19 pandemic to put three items at the top of the global agenda: health, climate change and a rebound which distributes economic benefits more fairly.

He will kick off that agenda on Friday by promising to share surplus vaccine doses with developing countries and calling for help to develop vaccines more quickly.

"By harnessing our collective ingenuity, we can ensure we have the vaccines, treatments and tests to be battle-ready for future health threats, as we beat Covid-19 and build back better together," Johnson said in a statement ahead of the meeting.

It took 314 days from the first identification of a COVID-19 cluster in China in December to the first successful vaccine trial results.

Britain hailed that as a huge achievement but said next time it must be done faster, backing a 100-day target previously set out by the Coalition for Epidemic Preparedness Innovations.

"As leaders of the G7 we must say today: never again," Johnson will tell the United States, Japan, Germany, France, Italy and Canada.

© Reuters. COVID-19 vaccinations in London

Johnson will commit to sending the majority of any surplus COVID-19 vaccines it has later in the year to the COVAX scheme which helps supply jabs to poorer nations. He will encourage other G7 nations to do the same.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.